Febrile neutropenia in patients treated with chemotherapy/immune checkpoint inhibition: a MASCC consensus statement

Tim Cooksley, Carme Font, Karin Thursky, Bernardo Rapoport, Claire Falandry, Florian Scotte · 2026

Read Febrile neutropenia in patients treated with chemotherapy/immune checkpoint inhibition: a MASCC consensus statement by Tim Cooksley, Carme Font, Karin Thursky, Bernardo Rapoport, Claire Falandry, Florian Scotte (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13421288.txt.

Description

Tim Cooksley leads a six-author MASCC consensus statement from 2026 on febrile neutropenia — fever with dangerously low white blood cells — in patients receiving chemotherapy combined with immune checkpoint inhibitors. This fever is a common emergency in cancer care, and sorting patients by risk decides who can safely be treated as an outpatient.

The group sets out ten position points for acute ambulatory care of low-risk patients. A MASCC score of 21 or more marks likely outpatient candidates, though the score was never validated for combined chemo-immunotherapy, and only one published paper met their search criteria. High-risk patients need standard sepsis management. The authors call for prospective and real-world data to firm up the pathway.

Catalog record

CREATORTim Cooksley, Carme Font, Karin Thursky, Bernardo Rapoport, Claire Falandry, Florian Scotte
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE23 KB
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13421288

Browse the full library · About the Tower of Babel